KCNT1 Inhibitors and Methods of Use
Summary
The USPTO published patent application US20260109692A1 covering KCNT1 inhibitors for treating neurological diseases and conditions related to excessive neuronal excitability or gain-of-function mutations in the KCNT1 gene. The application, filed on 2025-10-17 under Application No. 19361128, names James Thomas Reuberson, Sarah Jane Frith, and Vijayendar Reddy Yedulla as inventors. CPC classifications indicate the compounds fall within heterocyclic organic chemistry (C07D) with pharmaceutical applications (A61K).
“The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1).”
About this source
USPTO classification C07D covers heterocyclic organic compounds: the chemical core of most small-molecule drugs, including kinase inhibitors, GLP-1 receptor agonists, antibiotics, antivirals, and CNS therapies. Every newly published application in C07D lands in this feed, around 160 a month. Applications publish 18 months after filing, so this feed reveals what medicinal chemistry groups at Pfizer, Novartis, Roche, Shionogi, and others were synthesizing in the prior year and a half. Watch this if you run a medicinal chemistry program, file patent clearance for new drug candidates, scout competitor pipelines before clinical readouts, or track heterocyclic innovation across therapeutic areas.
What changed
The USPTO published patent application US20260109692A1 for KCNT1 inhibitors and methods of using such compounds for preventing and treating neurological diseases or disorders. The application covers compounds and compositions useful for treating conditions related to excessive neuronal excitability and gain-of-function mutations in the KCNT1 gene. The filing date is October 17, 2025, with Application No. 19361128.
Affected parties include pharmaceutical companies developing treatments for neurological disorders, researchers working on potassium channel inhibitors, and biotechnology firms focused on ion channel therapies. The publication represents a prior art event that may affect freedom-to-operate analyses for competing neurological drug development programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
KCNT1 INHIBITORS AND METHODS OF USE
Application US20260109692A1 Kind: A1 Apr 23, 2026
Inventors
James Thomas REUBERSON, Sarah Jane FRITH, Vijayendar Reddy YEDULLA
Abstract
The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.
CPC Classifications
C07D 413/14 A61K 31/4439 C07B 59/002
Filing Date
2025-10-17
Application No.
19361128
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.